

Felix Gutierrez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6934218/publications.pdf>

Version: 2024-02-01

224
papers

10,534
citations

57758

44
h-index

42399

92
g-index

258
all docs

258
docs citations

258
times ranked

12169
citing authors

#	ARTICLE	IF	CITATIONS
1	Massive Release of CD9+ Microvesicles in Human Immunodeficiency Virus Infection, Regardless of Virologic Control. <i>Journal of Infectious Diseases</i> , 2022, 225, 1040-1049.	4.0	13
2	Diabetes Does Not Increase the Risk of Hospitalization Due to COVID-19 in Patients Aged 50 Years or Older in Primary Care—APHOSDIAB—COVID-19 Multicenter Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 2092.	2.4	3
3	Clinical Performance of a Standardized Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Interferon- γ Release Assay for Simple Detection of T-Cell Responses After Infection or Vaccination. <i>Clinical Infectious Diseases</i> , 2022, 75, e338-e346.	5.8	27
4	Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral loads and low-grade systemic inflammation. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2257-2264.	3.0	17
5	Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade. <i>EBioMedicine</i> , 2022, 82, 104153.	6.1	8
6	Evaluation of the rapid antigen test Panbio COVID-19 in saliva and nasal swabs in a population-based point-of-care study. <i>Journal of Infection</i> , 2021, 82, 186-230.	3.3	56
7	Lack of detrimental effect of corticosteroids on antibody responses to SARS-CoV-2 and viral clearance in patients hospitalized with COVID-19. <i>Journal of Infection</i> , 2021, 82, 414-451.	3.3	10
8	Nasopharyngeal Panbio COVID-19 Antigen Performed at Point-of-Care Has a High Sensitivity in Symptomatic and Asymptomatic Patients With Higher Risk for Transmission and Older Age. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab059.	0.9	46
9	Performance of Saliva Specimens for the Molecular Detection of SARS-CoV-2 in the Community Setting: Does Sample Collection Method Matter?. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	3.9	21
10	Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2380-2393.	3.0	13
11	Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1678-1684.	6.0	34
12	Incidence of delayed asymptomatic COVID-19 recurrences in a 6-month longitudinal study. <i>Journal of Infection</i> , 2021, 82, 276-316.	3.3	5
13	Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study. <i>Journal of Clinical Immunology</i> , 2021, 41, 1490-1501.	3.8	95
14	COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study. <i>HIV Medicine</i> , 2021, 22, 867-876.	2.2	21
15	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 499.	7.4	498
16	Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study. <i>Journal of Autoimmunity</i> , 2021, 123, 102703.	6.5	37
17	Late reinfection with a different severe acute respiratory syndrome coronavirus-2 clade in a patient with refractory arterial hypertension: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 454.	0.8	0
18	Effectiveness and safety of antiretroviral treatment in pre- and postmenopausal women living with HIV in a multicentre cohort. <i>Antiviral Therapy</i> , 2021, 25, 335-340.	1.0	2

#	ARTICLE	IF	CITATIONS
19	SARS-CoV-2 Seroconversion and Viral Clearance in Patients Hospitalized With COVID-19: Viral Load Predicts Antibody Response. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab005.	0.9	52
20	Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 749657.	2.6	13
21	Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection. <i>Trials</i> , 2021, 22, 851.	1.6	6
22	Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 48-57.	1.1	10
23	Infection With <i>Chlamydia trachomatis</i> Increases the Risk of High-grade Anal Intraepithelial Neoplasia in People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2020, 70, 2161-2167.	5.8	4
24	How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain. <i>HIV Medicine</i> , 2020, 21, 128-134.	2.2	0
25	Rectal and seminal HIV-1 RNA decay towards virological suppression in infected MSM initiating dolutegravir/abacavir/lamivudine. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 668-674.	3.0	8
26	Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study. <i>Lancet HIV</i> , 2020, 7, e565-e573.	4.7	42
27	Preemptive interleukin-6 blockade in patients with COVID-19. <i>Scientific Reports</i> , 2020, 10, 16826.	3.3	35
28	Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106142.	2.5	6
29	Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3004-3014.	3.0	5
30	Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study. <i>AIDS Research and Therapy</i> , 2020, 17, 45.	1.7	1
31	Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3334-3343.	3.0	5
32	Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997-2017). <i>Scientific Reports</i> , 2020, 10, 16891.	3.3	3
33	Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study. <i>EBioMedicine</i> , 2020, 60, 102999.	6.1	71
34	Psychological distress in women and men living with HIV in Spain: a cross-sectional telephone survey. <i>Evidence-Based Mental Health</i> , 2020, 23, 91-99.	4.5	4
35	Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3517-3524.	3.0	6
36	COVID-19-associated encephalitis successfully treated with combination therapy. <i>Clinical Infection in Practice</i> , 2020, 7-8, 100053.	0.5	19

#	ARTICLE	IF	CITATIONS
37	Asma y EPOC en pacientes hospitalizados por COVID-19. Archivos De Bronconeumologia, 2020, 56, 604-606.	0.8	16
38	Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study. Clinical Infectious Diseases, 2019, 68, 597-606.	5.8	34
39	CD4 recovery is associated with genetic variation in IFN γ 3 and IL19 genes. Antiviral Research, 2019, 170, 104577.	4.1	7
40	HTLV-1 infection in solid organ transplant donors and recipients in Spain. BMC Infectious Diseases, 2019, 19, 706.	2.9	20
41	Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1. Antiviral Research, 2019, 170, 104543.	4.1	32
42	Spatiotemporal Characteristics of the Largest HIV-1 CRF02_AG Outbreak in Spain: Evidence for Onward Transmissions. Frontiers in Microbiology, 2019, 10, 370.	3.5	9
43	Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors. PLoS ONE, 2019, 14, e0221598.	2.5	7
44	Rapid subacute myelopathy following kidney transplantation from HTLV-1 donors: role of immunosuppressors and failure of antiretrovirals. Therapeutic Advances in Infectious Disease, 2019, 6, 204993611986802.	1.8	7
45	Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2019, 37, 373-379.	0.3	3
46	Performance of the cobas u 701 Analyzer in Urinary Tract Infection Screening. Annals of Laboratory Medicine, 2019, 39, 464-469.	2.5	4
47	Evolving understanding of cardiovascular, cerebrovascular and peripheral arterial disease in people living with HIV and role of novel biomarkers. A study of the Spanish CoRIS cohort, 2004-2015. PLoS ONE, 2019, 14, e0215507.	2.5	11
48	Risk of cancer in HIV-infected patients in Spain, 2004-2015. The CoRIS cohort study. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2019, 37, 502-508.	0.3	4
49	HIV co-infection in HTLV-1 carriers in Spain. Virus Research, 2019, 266, 48-51.	2.2	14
50	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet, The, 2019, 393, 2428-2438.	13.7	627
51	Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study. Nefrologia, 2019, 39, 497-505.	0.4	5
52	Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice. Journal of Antimicrobial Chemotherapy, 2019, 74, 1693-1700.	3.0	19
53	VDR rs2228570 Polymorphism Is Related to Non-Progression to AIDS in Antiretroviral Therapy Naïve HIV-Infected Patients. Journal of Clinical Medicine, 2019, 8, 311.	2.4	9
54	Clinical Presentation of Individuals With Human T-Cell Leukemia Virus Type-1 Infection in Spain. Open Forum Infectious Diseases, 2019, 6, ofz036.	0.9	8

#	ARTICLE	IF	CITATIONS
55	Contribution of Human Herpesvirus 8 and Herpes Simplex Type 2 to Progression of Carotid Intima-Media Thickness in People Living With HIV. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz041.	0.9	1
56	Glutaminolysis and lipoproteins are key factors in late immune recovery in successfully treated HIV-infected patients. <i>Clinical Science</i> , 2019, 133, 997-1010.	4.3	21
57	Genetic variation in CCR2 and CXCL12 genes impacts on CD4 restoration in patients initiating cART with advanced immunosuppression. <i>PLoS ONE</i> , 2019, 14, e0214421.	2.5	11
58	Riesgo de cáncer en personas con VIH en España, 2004-2015. Estudio de la cohorte CoRIS. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 502-508.	0.5	12
59	Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study. <i>Nefrología</i> , 2019, 39, 497-505.	0.4	1
60	Short-term Increase in Risk of Overweight and Concomitant Systolic Blood Pressure Elevation in Treatment-Naïve Persons Starting INSTI-based Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz491.	0.9	16
61	Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 373-379.	0.5	21
62	Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 195-202.	0.5	9
63	Cervicitis: etiología, diagnóstico y tratamiento. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 661-667.	0.5	13
64	Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010-2015. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 580-587.	0.5	4
65	Evaluation of the Virclia [®] automated chemiluminescent immunoassay system for diagnosing pneumonia caused by <i>Mycoplasma pneumoniae</i> . <i>Journal of Clinical Laboratory Analysis</i> , 2018, 32, e22431.	2.1	4
66	Decreasing rates of acute myocardial infarction in people living with HIV: a nationwide cohort study in Spain, 2004-2015. <i>HIV Medicine</i> , 2018, 19, 491-496.	2.2	8
67	Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapy. <i>Atherosclerosis</i> , 2018, 273, 28-36.	0.8	15
68	Sofosbuvir plus daclatasvir as an alternative for patients on haemodialysis with genotype 2 hepatitis C virus infection. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018, 36, 457.	0.5	1
69	High-grade anal intraepithelial neoplasia is associated with HIV-1 RNA rectal shedding in virologically suppressed MSM. <i>Aids</i> , 2018, 32, 1017-1024.	2.2	5
70	Low-Level Viremia Is Associated With Clinical Progression in HIV-Infected Patients Receiving Antiretroviral Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 329-337.	2.1	53
71	Asociación de obesidad general y abdominal con hipertensión, dislipemia y presencia de prediabetes en el estudio PREDAPS. <i>Revista Española De Cardiología</i> , 2018, 71, 170-177.	1.2	33
72	Executive summary of the consensus document on osteoporosis in HIV-infected individuals. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018, 36, 312-314.	0.5	7

#	ARTICLE	IF	CITATIONS
73	Developments in early diagnosis and therapy of HIV infection in newborns. Expert Opinion on Pharmacotherapy, 2018, 19, 13-25.	1.8	10
74	Barriers to health care services for migrants living with HIV in Spain. European Journal of Public Health, 2018, 28, 451-457.	0.3	23
75	Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial. Journal of Antimicrobial Chemotherapy, 2018, 73, 2444-2451.	3.0	6
76	Role of HIV in the desire of procreation and motherhood in women living with HIV in Spain: a qualitative approach. BMC Women's Health, 2018, 18, 24.	2.0	3
77	Combined Effect of Sex and Age in Response to Antiretroviral Therapy in HIV-Infected Patients. Antiviral Therapy, 2017, 22, 21-29.	1.0	4
78	Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection. Clinical Microbiology and Infection, 2017, 23, 409.e5-409.e8.	6.0	8
79	Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016. Enfermedades Infecciosas Y Microbiología Clínica, 2017, 35, 377-383.	0.5	11
80	Contribution of Oxidative Stress to Non-AIDS Events in HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, e36-e44.	2.1	10
81	Severe skull base osteomyelitis caused by Pseudomonas aeruginosa with successful outcome after prolonged outpatient therapy with continuous infusion of ceftazidime and oral ciprofloxacin: a case report. Journal of Medical Case Reports, 2017, 11, 48.	0.8	13
82	Genotypic tropism testing of proviral <sc>DNA</sc> to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the <sc>PROTEST</sc> study. HIV Medicine, 2017, 18, 482-489.	2.2	1
83	Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet, The, 2017, 390, 1499-1510.	13.7	391
84	Infección por el VIH/sida: ¿El principio del fin de la primera gran pandemia contemporánea?. Revista Clínica Española, 2017, 217, 468-472.	0.6	2
85	Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016. Enfermedades Infecciosas Y Microbiología Clínica (English Ed), 2017, 35, 377-383.	0.3	0
86	Thymic Function Failure Is Associated With Human Immunodeficiency Virus Disease Progression. Clinical Infectious Diseases, 2017, 64, 1191-1197.	5.8	30
87	Procalcitonin for selecting the antibiotic regimen in outpatients with low-risk community-acquired pneumonia using a rapid point-of-care testing: A single-arm clinical trial. PLoS ONE, 2017, 12, e0175634.	2.5	8
88	Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach. PLoS ONE, 2017, 12, e0184329.	2.5	6
89	Statins in HIV-Infected Patients: Potential Beneficial Effects and Clinical Use. AIDS Reviews, 2017, 19, 59-71.	1.0	12
90	Incidence and clearance of anal high-risk human papillomavirus in HIV-positive men who have sex with men. Aids, 2016, 30, 37-44.	2.2	46

#	ARTICLE	IF	CITATIONS
91	Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio. <i>Medicine (United States)</i> , 2016, 95, e3108.	1.0	24
92	Clinical outcomes of patients infected with HIV through use of injected drugs compared to patients infected through sexual transmission: late presentation, delayed anti-retroviral treatment and higher mortality. <i>Addiction</i> , 2016, 111, 1235-1245.	3.3	26
93	Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013. <i>Journal of Infection</i> , 2016, 72, 587-596.	3.3	60
94	Executive summary of the GESIDA/National AIDS Plan Consensus Document on Antiretroviral Therapy in Adults Infected by the Human Immunodeficiency Virus (Updated January 2016). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 439-451.	0.5	16
95	Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 517-523.	0.5	12
96	Effectiveness and safety of an abacavir/lamivudine+rilpivirine regimen for the treatment of HIV-1 infection in naive patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3510-3514.	3.0	7
97	Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 171.	7.4	1,076
98	Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir-based antiretroviral therapy. <i>HIV Medicine</i> , 2016, 17, 653-661.	2.2	20
99	Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining Conditions. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw097.	0.9	37
100	Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 516.e1-516.e18.	0.5	11
101	The CD4/CD8 Ratio is Inversely Associated with Carotid Intima-Media Thickness Progression in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Treatment. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 648-653.	1.1	26
102	Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe. <i>Clinical Infectious Diseases</i> , 2016, 62, 655-663.	5.8	135
103	Analysis of Non-AIDS-Defining Events in HIV Controllers. <i>Clinical Infectious Diseases</i> , 2016, 62, 1304-1309.	5.8	34
104	Oxidative Stress Predicts All-Cause Mortality in HIV-Infected Patients. <i>PLoS ONE</i> , 2016, 11, e0153456.	2.5	40
105	Impact of Prior Virological Failure and Nucleos(t)ide Genotypic Resistance Mutations on the Efficacy of Switching from Ritonavir-Boosted Protease Inhibitors to Raltegravir. <i>Antiviral Therapy</i> , 2015, 20, 487-492.	1.0	8
106	Vitamin D deficiency: One more piece of the puzzle of cardiovascular risk in human immunodeficiency virus-infected patients?. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 118-120.	0.2	0
107	Shorter Telomere Length Predicts Poorer Immunological Recovery in Virologically Suppressed HIV-1-Infected Patients Treated With Combined Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 21-29.	2.1	23
108	Differential Body Composition Effects of Protease Inhibitors Recommended for Initial Treatment of HIV Infection: A Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2015, 60, 811-820.	5.8	26

#	ARTICLE	IF	CITATIONS
109	Executive summary of the consensus document on metabolic disorders and cardiovascular risk in patients with HIV infection. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 41-47.	0.5	4
110	Boosted Lopinavirâ€“ Versus Boosted Atazanavirâ€“Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. <i>Clinical Infectious Diseases</i> , 2015, 60, 1262-1268.	5.8	6
111	First Human Systemic Infection Caused by <i>Spiroplasma</i> . <i>Journal of Clinical Microbiology</i> , 2015, 53, 719-721.	3.9	29
112	Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort. <i>Antiviral Research</i> , 2015, 117, 69-74.	4.1	69
113	Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. <i>Lancet HIV</i> , 2015, 2, e335-e343.	4.7	52
114	Dual treatment with atazanavirâ€“ritonavir plus lamivudine versus triple treatment with atazanavirâ€“ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. <i>Lancet Infectious Diseases</i> , 2015, 15, 775-784.	9.1	122
115	Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3087-3095.	3.0	13
116	Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 544-556.	0.5	10
117	Epidemiology of animal bites and other potential rabies exposures and anti-rabies vaccine utilization in a rural area in Southern Ethiopia. <i>Annals of Agricultural and Environmental Medicine</i> , 2015, 22, 76-79.	1.0	24
118	Incidence of Hepatitis C Virus (HCV) in a Multicenter Cohort of HIV-Positive Patients in Spain 2004â€“2011: Increasing Rates of HCV Diagnosis but Not of HCV Seroconversions. <i>PLoS ONE</i> , 2014, 9, e116226.	2.5	19
119	CNS safety at 48-week of switching to ATV/r plus 3TC or two nucleos(t)ides in HIV-suppressed patients on stable ART: the SALT neurocognitive sub-study. <i>Journal of the International AIDS Society</i> , 2014, 17, 19656.	3.0	4
120	The effects of Maraviroc on liver fibrosis in HIV/HCV coâ€“infected patients. <i>Journal of the International AIDS Society</i> , 2014, 17, 19643.	3.0	23
121	Recurrence of active tuberculosis following resumption of anti-TNF-Î± therapy in a patient with Crohn's disease [Correspondence]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 249-250.	1.2	8
122	Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir. <i>HIV Medicine</i> , 2014, 15, 330-338.	2.2	25
123	Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavirâ€“boosted protease inhibitorâ€“based versus a nonnucleoside reverse transcriptase inhibitorâ€“based firstâ€“line regimen. <i>HIV Medicine</i> , 2014, 15, 547-556.	2.2	6
124	X4 tropic viruses are on the rise in recent HIV-1 seroconverters in Spain. <i>Aids</i> , 2014, 28, 1603-1609.	2.2	14
125	Risk of clinically significant depression in HIV-infected patients: effect of antiretroviral drugs. <i>HIV Medicine</i> , 2014, 15, 213-223.	2.2	30
126	Long-term effects of an intensive intervention in HIV-infected patients with moderateâ€“high atherosclerotic cardiovascular risk. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3051-3056.	3.0	8

#	ARTICLE	IF	CITATIONS
127	Simeprevir (TMC435) With Pegylated Interferon/Ribavirin in Patients Coinfected With HCV Genotype 1 and HIV-1: A Phase 3 Study. <i>Clinical Infectious Diseases</i> , 2014, 59, 1579-1587.	5.8	63
128	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. <i>Clinical Infectious Diseases</i> , 2014, 58, 1312-1321.	5.8	140
129	Anal tuberculosis complicating anti-TNF α therapy. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014206976-bcr2014206976.	0.5	5
130	Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study. <i>Journal of the International AIDS Society</i> , 2014, 17, 19520.	3.0	2
131	Coinfection with Human Herpesvirus 8 Is Associated with Persistent Inflammation and Immune Activation in Virologically Suppressed HIV-Infected Patients. <i>PLoS ONE</i> , 2014, 9, e105442.	2.5	21
132	Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management. <i>AIDS Reviews</i> , 2014, 16, 199-212.	1.0	36
133	Consensus document on the management of renal disease in HIV-infected patients. <i>Nefrologia</i> , 2014, 34 Suppl 2, 1-81.	0.4	8
134	Executive summary of the consensus document on the management of renal disease in HIV-infected patients. <i>Nefrologia</i> , 2014, 34, 768-88.	0.4	1
135	Short-Term and Long-Term Clinical and Immunological Consequences of Stopping Antiretroviral Therapy in HIV-Infected Patients with Preserved Immune Function. <i>Antiviral Therapy</i> , 2013, 18, 125-130.	1.0	17
136	Executive summary of the Consensus Document of GeSIDA and Spanish Secretariat for the National Plan on AIDS on combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2013). <i>Enfermedades Infecciosas Y Microbiologa Clnica</i> , 2013, 31, 604-613.	0.5	4
137	Negative effect of immunosuppressive therapy in the performance of the QuantiFERON Gold In-Tube test in patients with immune-mediated inflammatory diseases. <i>Clinical and Experimental Medicine</i> , 2013, 13, 177-186.	3.6	27
138	Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 409-413.	3.0	19
139	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥ 200 Cells/ μ L in the Post-Combination Antiretroviral Therapy Era. <i>Clinical Infectious Diseases</i> , 2013, 57, 1038-1047.	5.8	92
140	Dolutegravir plus AbacavirLamivudine for the Treatment of HIV-1 Infection. <i>New England Journal of Medicine</i> , 2013, 369, 1807-1818.	27.0	697
141	Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients. <i>Aids</i> , 2013, 27, 181-189.	2.2	53
142	Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1994-2002.	3.0	9
143	Inequalities in HIV disease management and progression in migrants from Latin America and Sub-Saharan Africa living in Spain. <i>HIV Medicine</i> , 2013, 14, 273-283.	2.2	39
144	Human Infection with <i>Rickettsia sibirica mongolitimonae</i> , Spain, 2007-2011. <i>Emerging Infectious Diseases</i> , 2013, 19, 267-269.	4.3	40

#	ARTICLE	IF	CITATIONS
145	Estimating the Burden of Pneumococcal Pneumonia among Adults: A Systematic Review and Meta-Analysis of Diagnostic Techniques. <i>PLoS ONE</i> , 2013, 8, e60273.	2.5	329
146	Increased Carotid Intima-Media Thickness Associated with Antibody Responses to Varicella-Zoster Virus and Cytomegalovirus in HIV-Infected Patients. <i>PLoS ONE</i> , 2013, 8, e64327.	2.5	22
147	CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE. <i>PLoS Medicine</i> , 2012, 9, e1001194.	8.4	145
148	Idiopathic ileocolitis with perforation associated with HIV infection: thalidomide treatment. <i>International Journal of STD and AIDS</i> , 2012, 23, 830-832.	1.1	1
149	Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2873-2878.	3.2	62
150	Short Communication: Early Changes in Parathyroid Hormone Concentrations in HIV-Infected Patients Initiating Antiretroviral Therapy with Tenofovir. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 242-246.	1.1	64
151	Plasma Raltegravir Exposure Influences the Antiviral Activity and Selection of Resistance Mutations. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 156-164.	1.1	18
152	<i>Trypanosoma cruzi</i> infection in Elche (Spain): comparison of the seroprevalence in immigrants from Paraguay and Bolivia. <i>Pathogens and Global Health</i> , 2012, 106, 102-106.	2.3	20
153	Multicenter epidemiological and clinical study on imported Chagas diseases in Alicante, Spain. <i>Pathogens and Global Health</i> , 2012, 106, 340-345.	2.3	19
154	Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy. <i>Antiviral Therapy</i> , 2012, 17, 597.	1.0	0
155	Differences in the causes of death of HIV-positive patients in a cohort study by data sources and coding algorithms. <i>Aids</i> , 2012, 26, 1829-1834.	2.2	27
156	Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. <i>Aids</i> , 2012, 26, 2315-2326.	2.2	104
157	Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class. <i>Clinical Microbiology and Infection</i> , 2012, 18, E485-E490.	6.0	26
158	Prevalence of HIV, HBV, HCV, HTLV and <i>Treponema pallidum</i> among patients attending a rural hospital in Southern Ethiopia. <i>Journal of Clinical Virology</i> , 2012, 53, 268-269.	3.1	6
159	Contribution of Interferon gamma release assays testing to the diagnosis of latent tuberculosis infection in HIV-infected patients: A comparison of QuantiFERON-TB Gold In Tube, T-SPOT.TB and tuberculin skin test. <i>BMC Infectious Diseases</i> , 2012, 12, 169.	2.9	46
160	Gender differential on characteristics and outcome of leprosy patients admitted to a long-term care rural hospital in South-Eastern Ethiopia. <i>International Journal for Equity in Health</i> , 2012, 11, 56.	3.5	19
161	Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy. <i>Retrovirology</i> , 2012, 9, 68.	2.0	7
162	Chagas disease in Latin American pregnant immigrants: experience in a non-endemic country. <i>Archives of Gynecology and Obstetrics</i> , 2012, 285, 919-923.	1.7	19

#	ARTICLE	IF	CITATIONS
163	Impact of antiretroviral therapy interruption on plasma biomarkers of cardiovascular risk and lipids: 144-week final data from the STOPAR study. <i>HIV Medicine</i> , 2012, 13, 488-498.	2.2	9
164	Rubella immune status among immigrant and nonimmigrant women in Spain. <i>Journal of Medical Virology</i> , 2012, 84, 548-550.	5.0	12
165	Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists. <i>AIDS Reviews</i> , 2012, 14, 208-17.	1.0	35
166	Clinical Utility of Maraviroc. <i>Clinical Drug Investigation</i> , 2011, 31, 527-542.	2.2	29
167	Seroprevalence of HIV-1, HBV, HTLV-1 and <i>Treponema pallidum</i> among pregnant women in a rural hospital in Southern Ethiopia. <i>Journal of Clinical Virology</i> , 2011, 51, 83-85.	3.1	46
168	Seroprevalence of HTLV infection among immigrant pregnant women in the Mediterranean coast of Spain. <i>Journal of Clinical Virology</i> , 2011, 51, 192-194.	3.1	6
169	Mapping of Chagas disease research: analysis of publications in the period between 1940 and 2009. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2011, 44, 708-716.	0.9	13
170	Predictors of Pneumococcal Co-infection for Patients with Pandemic (H1N1) 2009 Influenza. <i>Emerging Infectious Diseases</i> , 2011, 17, 1475-8.	4.3	8
171	A Highly Sensitive and Specific Model for Predicting HIV-1 Tropism in Treatment-Experienced Patients Combining Interpretation of V3 Loop Sequences and Clinical Parameters. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, 51-58.	2.1	12
172	Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy. <i>Antiviral Therapy</i> , 2011, 17, 577-583.	1.0	7
173	Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients – Impact of HIV subtypes and prior raltegravir experience. <i>Antiviral Research</i> , 2011, 90, 164-167.	4.1	48
174	Seroprevalence of <i>Toxoplasma gondii</i> infection among immigrant and native pregnant women in Eastern Spain. <i>Parasitology Research</i> , 2011, 109, 1447-1452.	1.6	41
175	Evaluation of endothelial function and subclinical atherosclerosis in association with hepatitis C virus in HIV-infected patients: a cross-sectional study. <i>BMC Infectious Diseases</i> , 2011, 11, 265.	2.9	33
176	Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir. <i>BMC Infectious Diseases</i> , 2011, 11, 40.	2.9	32
177	Treatment for hepatitis C virus with pegylated interferon- α plus ribavirin induces anti-atherogenic effects on cardiovascular risk biomarkers in HIV-infected and -uninfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1861-1868.	3.0	17
178	Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. <i>Aids</i> , 2011, 25, 761-766.	2.2	26
179	Association of Patients' Geographic Origins with Viral Hepatitis Co-infection Patterns, Spain. <i>Emerging Infectious Diseases</i> , 2011, 17, 1116-1119.	4.3	6
180	Association of Patients' Geographic Origins with Viral Hepatitis Co-infection Patterns, Spain. <i>Emerging Infectious Diseases</i> , 2011, 17, 1116-1119.	4.3	4

#	ARTICLE	IF	CITATIONS
181	The role of HIV and antiretroviral therapy in bone disease. <i>AIDS Reviews</i> , 2011, 13, 109-18.	1.0	42
182	Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database. <i>Aids</i> , 2010, 24, 469-471.	2.2	13
183	Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. <i>Aids</i> , 2010, 24, F1-F9.	2.2	60
184	Endothelial function is impaired in HIV-infected patients with lipodystrophy. <i>Antiviral Therapy</i> , 2010, 15, 101-110.	1.0	37
185	Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. A call for caution. <i>Journal of Infection</i> , 2010, 61, 189-190.	3.3	35
186	Diagnostic accuracy of sTREM-1 to identify infection in critically ill patients with systemic inflammatory response syndrome. <i>Clinical Biochemistry</i> , 2010, 43, 720-724.	1.9	38
187	Clinical evaluation of rapid point-of-care testing for detection of novel influenza A (H1N1) virus in a population-based study in Spain. <i>Clinical Microbiology and Infection</i> , 2010, 16, 1358-1361.	6.0	33
188	Drug Resistance Mutations in HIV-Infected Patients in the Spanish Drug Resistance Database Failing Tipranavir and Darunavir Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3018-3020.	3.2	8
189	Performance of Genotypic Algorithms for Predicting HIV-1 Tropism Measured against the Enhanced-Sensitivity Trofile Coreceptor Tropism Assay. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4135-4139.	3.9	26
190	Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. <i>Aids</i> , 2010, 24, 1697-1707.	2.2	174
191	Comparison of Combined Nose-Throat Swabs with Nasopharyngeal Aspirates for Detection of Pandemic Influenza A/H1N1 2009 Virus by Real-Time Reverse Transcriptase PCR. <i>Journal of Clinical Microbiology</i> , 2010, 48, 3492-3495.	3.9	40
192	<i>Mycobacterium marinum</i> infection complicated by anti-tumour necrosis factor therapy. <i>Journal of Medical Microbiology</i> , 2010, 59, 617-621.	1.8	37
193	Death rates in HIV-positive antiretroviral-naïve patients with CD4 count greater than 350 cells per μ L in Europe and North America: a pooled cohort observational study. <i>Lancet</i> , 2010, 376, 340-345.	13.7	82
194	Cryoglobulinemic glomerulonephritis in chronic hepatitis B infection. <i>Renal Failure</i> , 2010, 32, 518-522.	2.1	17
195	Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. <i>AIDS Reviews</i> , 2010, 12, 135-48.	1.0	42
196	Pharmacokinetics of Fosamprenavir plus Ritonavir in Human Immunodeficiency Virus Type 1-Infected Adult Subjects with Hepatic Impairment. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 5185-5196.	3.2	15
197	Decrease in Serial Prevalence of Coinfection with Hepatitis C Virus among HIV-Infected Patients in Spain, 1997-2006. <i>Clinical Infectious Diseases</i> , 2009, 48, 1467-1470.	5.8	52
198	A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate-high cardiovascular risk. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 589-598.	3.0	15

#	ARTICLE	IF	CITATIONS
199	Microbiology and Outcome of Iliopsoas Abscess in 124 Patients. <i>Medicine (United States)</i> , 2009, 88, 120-130.	1.0	131
200	Risk Factors, CD4 Long-Term Evolution and Mortality of HIV-Infected Patients who Persistently Maintain Low CD4 Counts, Despite Virological Response to HAART. <i>Current HIV Research</i> , 2009, 7, 612-619.	0.5	26
201	A bibliometric overview of infectious diseases research in European countries (2002â€“2007). <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2009, 28, 713-716.	2.9	24
202	Considerations on ankleâ€“brachial index interpretation in HIVâ€“1 infected patients. <i>HIV Medicine</i> , 2009, 10, 395-395.	2.2	1
203	Efficacy and Safety of Switching From Boosted Lopinavir to Boosted Atazanavir in Patients With Virological Suppression Receiving a LPV/r-Containing HAART: The ATAZIP Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 29-36.	2.1	81
204	A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 290-297.	2.1	73
205	Remission of minimal change disease in Type 2 diabetes after streptococcus bacteremia. <i>Clinical Nephrology</i> , 2009, 71, 179-182.	0.7	1
206	HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines. <i>AIDS Reviews</i> , 2009, 11, 39-51.	1.0	16
207	Improving Outcomes of Elderly Patients with Community-Acquired Pneumonia. <i>Drugs and Aging</i> , 2008, 25, 585-610.	2.7	23
208	First case of post-endoscopic retrograde cholangiopancreatography bacteraemia caused by <i>Acinetobacter ursingii</i> in a patient with choledocholithiasis and cholangitis. <i>Journal of Medical Microbiology</i> , 2008, 57, 1170-1171.	1.8	8
209	Low Prevalence of Peripheral Arterial Disease in HIV-Infected Patients With Multiple Cardiovascular Risk Factors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 126-127.	2.1	25
210	High-Density Lipoprotein Cholesterol in HIV-Infected Patients: Evidence for an Association with HIV-1 Viral Load, Antiretroviral Therapy Status, and Regimen Composition. <i>AIDS Patient Care and STDs</i> , 2008, 22, 569-575.	2.5	58
211	Relationship between ankleâ€“brachial index and carotid intima-media thickness in HIV-infected patients. <i>Aids</i> , 2008, 22, 1369-1371.	2.2	26
212	Patients Characteristics and Clinical Implications of Suboptimal CD4 T-Cell Gains After 1 Year of Successful Antiretroviral Therapy. <i>Current HIV Research</i> , 2008, 6, 100-107.	0.5	66
213	Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 698-704.	3.0	76
214	Influence of Antiretroviral Therapy on Oxidative Stress and Cardiovascular Risk: A Prospective Cross-Sectional Study in HIV-Infected Patients. <i>Clinical Therapeutics</i> , 2007, 29, 1448-1455.	2.5	71
215	The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. <i>Atherosclerosis</i> , 2007, 195, 167-171.	0.8	52
216	Delay in the Initiation of HAART, Poorer Virological Response, and Higher Mortality among HIV-Infected Injecting Drug Users in Spain. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 715-723.	1.1	63

#	ARTICLE	IF	CITATIONS
217	Occult lymphadenopathic Kaposi's sarcoma associated with severe pulmonary hypertension: A clinical hint about the potential role of HHV-8 in HIV-related pulmonary hypertension?. <i>Journal of Clinical Virology</i> , 2006, 37, 79-82.	3.1	22
218	Clinical Outcome of HIV-Infected Patients with Sustained Virologic Response to Antiretroviral Therapy: Long-Term Follow-Up of a Multicenter Cohort. <i>PLoS ONE</i> , 2006, 1, e89.	2.5	42
219	The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. <i>Journal of Infection</i> , 2006, 53, 166-174.	3.3	179
220	Usefulness of Procalcitonin Levels in Community-Acquired Pneumonia According to the Patients Outcome Research Team Pneumonia Severity Index. <i>Chest</i> , 2005, 128, 2223-2229.	0.8	171
221	Low Frequency of Renal Function Impairment During One-Year of Therapy with Tenofovir-Containing Regimens in the Real-World: A Case-Control Study. <i>AIDS Patient Care and STDs</i> , 2005, 19, 421-424.	2.5	41
222	Prediction of Neuropsychiatric Adverse Events Associated with Long-Term Efavirenz Therapy, Using Plasma Drug Level Monitoring. <i>Clinical Infectious Diseases</i> , 2005, 41, 1648-1653.	5.8	202
223	Geography of medical publications. An overview of HIV/AIDS research in 2003. <i>Aids</i> , 2005, 19, 219-220.	2.2	8
224	Evaluation of the Immunochromatographic Binax NOW Assay for Detection of <i>Streptococcus pneumoniae</i> Urinary Antigen in a Prospective Study of Community-Acquired Pneumonia in Spain. <i>Clinical Infectious Diseases</i> , 2003, 36, 286-292.	5.8	261